

Abstract 12 Table 1 Baseline characteristics

Characteristic	Patients (n = 27)
Age, median (range)	62 (35-78)
Histology	
High grade serous	25 (92.6%)
Intermediate grade serous	1 (3.7%)
Mixed	1 (3.7%)
ECOG performance status	
0	17 (63%)
1	10 (37%)
Prior number of lines, median (range)	4 (2-9)
Prior platinum lines, median (range)	2 (1-5)
Platinum status at enrollment	
Platinum-resistant	13 (48%)
Platinum-refractory	14 (52%)
Prior antiangiogenic therapy with bevacizumab	
Yes	22 (81%)
No	5 (19%)
Prior PARP inhibitor therapy	
Yes	20 (74%)
No	7 (26%)
Baseline genomic profiles	
Tumor PD-L1 expression	
Positive	1 (3.7%)
Negative	25 (92.6%)
Unknown	1 (3.7%)
BRCA1/2 mutations	
Positive	8 (30%)
Negative	19 (70%)
Microsatellite instability status	
Stable	19 (70%)
Unknown	8 (30%)
Tumor mutational load	
Low	13 (48%)
Intermediate	4 (15%)
Unknown	10 (37%)
Response & PFS from last prior line before enrollment into VIRO-15 trial	
ORR by RECIST	4/27 (15%)
ORR by CA-125	5/24 (21%)
PFS (mos), median (95% CI)	4.5 (2.9–5.8)
PFS-6-month	30%

T-cells and upregulation of STAT1 expression ($p=0.008$) were demonstrated.

Conclusions Despite PRROC, prior bevacizumab, and progression on last therapy, the majority of patients achieved RECIST response with median PFS exceeding their prior line of therapy. Virus-induced changes in the tumor microenvironment may explain the apparent clinical reversal of platinum resistance.

IGCS20_1440

13

EFFICACY ON INDIVIDUALIZED STARTING DOSE (ISD) AND FIXED STARTING DOSE (FSD) OF NIRAPARIB PER INVESTIGATOR-ASSESSMENT (IA) IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (OC)

¹W Graybill*, ²M Mirza, ³A González-Martin, ⁴D O'Malley, ⁵L Gaba, ⁶OWS Yap, ⁷E Guerra, ⁸PG Rose, ⁹J Baurain, ¹⁰S Ghamande, ¹¹H Denys, ¹²E Prendergast, ¹³C Pisano, ¹⁴P Follana, ¹⁵E Braicu, ¹⁶PM Calvert, ¹⁷J Korach, ¹⁸Y Li, ¹⁹D Gupta, ¹⁹BJ Monk. ¹Gynecologic Oncology Group (GOG) and Department of Gynecologic Oncology, Medical University of South Carolina, USA; ²Nordic Society of Gynaecological Oncology (NSGO) and Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark; ³Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Medical Oncology Department, Clínica Universidad de Navarra, Spain; ⁴The Ohio State University – James CCC, USA; ⁵Hospital Clinic de Barcelona, Medical Oncology Department, Spain; ⁶University Gynecologic Oncology, USA; ⁷Hospital Universitario Ramón y Cajal, Spain; ⁸Cleveland Clinic, USA; ⁹Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Belgium; ¹⁰Georgia Cancer Center, Augusta University, USA; ¹¹Ghent University Hospital, Belgium; ¹²Minnesota Oncology, USA; ¹³Istituto Nazionale Tumori IRCCS Fondazione Pascale, Italy; ¹⁴GINECO and Centre Antoine Lacassagne, France; ¹⁵Charité Medical University, Germany; ¹⁶Cancer Trials Ireland, Ireland; ¹⁷Department of Gynecologic Oncology, Chaim Sheba Medical Center, Israel; ¹⁸GlaxoSmithKline, USA; ¹⁹Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, USA

10.1136/ijgc-2020-IGCS.13

Introduction Niraparib is a poly(ADP-ribose) polymerase inhibitor approved for maintenance treatment of patients with newly diagnosed or recurrent OC that responded to platinum-based

Abstract 13 Table 1

Median PFS	IA PFS in the overall population and the ISD and FSD subgroups, HR (95% CI)	
	Original data cut 17 May 2019	Updated data cut 17 Nov 2019
Overall, N=733	0.63 (0.51, 0.76) P<0.0001	0.64 (0.53, 0.77) P<0.0001
FSD, n=487	0.60 (0.47, 0.77)	0.62 (0.49, 0.78)
ISD, n=246	0.68 (0.48, 0.96)	0.68 (0.49, 0.94)

FSD, fixed starting dose; HR, hazard ratio; IA, investigator assessment; ISD, individualized starting dose; PFS, progression-free survival.

chemotherapy and treatment in heavily-pretreated recurrent OC. Here we report efficacy in patients receiving the FSD and ISD in the PRIMA/ENGOT-OV26/GOG-3012 trial (NCT02655016).

Methods This double-blind, placebo-controlled, phase 3 study randomized 733 patients to receive niraparib or placebo for 36 months or until disease progression/toxicity. A protocol amendment introduced ISD: 200 mg in patients with body weight <77 kg or platelets <150,000/ μ L, or 300 mg in all others. The primary endpoint was PFS by blinded independent central review (BICR). IA PFS was a sensitivity analysis. At the primary analysis data cut, follow-up was 11.2 months and 17.1 months in the ISD and FSD subgroups, respectively. An ad hoc analysis of IA PFS was performed using an updated data cut with additional 6 months follow-up.

Results BICR and IA PFS were highly concordant in the overall population. Efficacy of niraparib based on IA PFS in FSD vs ISD subgroups for each data cut were similar (table 1). Dose interruptions, modifications, and hematologic toxicity were lower with the ISD. Exposure–response data supported the clinical data.

Conclusions The 200- or 300-mg ISD by baseline body weight and platelet counts demonstrated comparable efficacy while improving the safety profile of niraparib. Use of this regimen for first-line maintenance of advanced OC patients is approved by the US FDA.

Funded by: GlaxoSmithKline

NCT: NCT02655016

Plenary V

IGCS20_1271

14

PHASE II TRIAL EVALUATING EFFICACY AND SAFETY OF STANDARD OF CARE WITH OR WITHOUT BEVACIZUMAB IN PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

¹N Nishikawa*, ²T Shoji, ¹T Enomoto, ³M Abe, ⁴A Okamoto, ⁵T Saito, ⁶T Oishi, ⁷S Nagase, ⁸M Mori, ⁹Y Inokuchi, ¹⁰SK Kamiura, ¹¹T Sugiyama. ¹Niigata University, Japan; ²Iwate Medical University School of Medicine, Japan; ³Shizuoka Cancer Center, Japan; ⁴The Jikei University School of Medicine, Japan; ⁵Hachinohe Red Cross Hospital, Japan; ⁶Tottori University School of Medicine, Japan; ⁷Yamagata University, Japan; ⁸Aichi Cancer Center Hospital, Japan; ⁹Kitasato University Hospital, Japan; ¹⁰Osaka International Cancer Institute, Japan; ¹¹St. Mary's Hospital, Japan

10.1136/ijgc-2020-IGCS.14

Introduction There are no ongoing clinical trials investigating bevacizumab efficacy beyond disease progression in platinum-